Takeda Pharmaceutical Co says it has initiated a late-stage programme for TAK-875, an investigational therapy for type 2 diabetes.
The drug is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. Takeda noted that TAK-875 is the first treatment in this class to reach late-stage studies.
GPR40 agonists have a mechanism of action for type 2 diabetes different from that of sulfonylureas, such as Sanofi's Amaryl (glimepiride). They work by selectively improving glucose-dependent insulin secretion with a potential for reduced risk of hypoglycaemia.
Phase III trials got underway in Japan last month and the first late-stage study in the US/Europe programme will enrol 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise, at 140 sites. The latter's study's primary endpoint will be the change in HbA1c at week 24; results are expected by 2014.
In July, Takeda resubmitted two New Drug Applications to regulators in the USA for its investigational type 2 diabetes therapy alogliptin, a selective dipeptidyl peptidase IV inhibitor (DPP-4) inhibitor, and the fixed-dose combination of the latter and the Japanese drugmaker's Actos (pioglitazone).
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.